EP Patent

EP2620140A1 — Crizotinib containing compositions

Assigned to Ratiopharm GmbH · Expires 2013-07-31 · 13y expired

What this patent protects

The present invention relates to a pharmaceutical composition containing non-crystalline crizotinib together with a surface stabiliser. The invention further relates to methods of preparing stable pharmaceutical compositions containing non-crystalline crizotinib. Further, the inv…

USPTO Abstract

The present invention relates to a pharmaceutical composition containing non-crystalline crizotinib together with a surface stabiliser. The invention further relates to methods of preparing stable pharmaceutical compositions containing non-crystalline crizotinib. Further, the invention relates to an oral dosage form containing the above pharmaceutical composition and to methods of producing said oral dosage form.

Drugs covered by this patent

Patent Metadata

Patent number
EP2620140A1
Jurisdiction
EP
Classification
—
Expires
2013-07-31
Drug substance claim
No
Drug product claim
No
Assignee
Ratiopharm GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.